| 臺大學術典藏 |
2022-02-14T07:10:41Z |
Successful management of a ROS1-rearranged pulmonary pleomorphic carcinoma using serial tyrosine kinase inhibitors
|
Wu C.-W.; Yang C.-Y.; YIH-LEONG CHANG; Shih J.-Y. |
| 臺大學術典藏 |
2022-02-14T07:10:40Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-14T07:10:39Z |
Multi-kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin-related protein 1
|
Chung K.-P.; Huang Y.-L.; Chen Y.-J.; Juan Y.-H.; Hsu C.-L.; Nakahira K.; Huang Y.-T.; Lin M.-W.; Wu S.-G.; Shih J.-Y.; YIH-LEONG CHANG; Yu C.-J. |
| 臺大學術典藏 |
2022-02-14T07:10:38Z |
Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer
|
Lin C.-Y.; Huang K.-Y.; Lin Y.-C.; Yang S.-C.; Chung W.-C.; YIH-LEONG CHANG; Shih J.-Y.; Ho C.-C.; Lin C.-A.; Shih C.-C.; Chang Y.-H.; Kao S.-H.; Yang P.-C. |
| 臺大學術典藏 |
2022-01-22T00:04:55Z |
Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer
|
Chang, L. K.; Kuo, Y. W.; Wu, S. G.; Chung, K. P.; Shih, J. Y. |
| 臺大學術典藏 |
2022-01-14T03:59:36Z |
Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers
|
JO-PAI CHEN; Lo Y.; Yu C.-J.; Hsu C.; Shih J.-Y.; Yang C.-H. |
| 臺大學術典藏 |
2022-01-08T04:31:30Z |
Clinicopathological features and survival outcomes of primary pulmonary invasive mucinous adenocarcinoma
|
Gow C.-H.; MIN-SHU HSIEH; Liu Y.-N.; Lee Y.-H.; Shih J.-Y. |
| 國立成功大學 |
2022 |
miR-21 upregulation exacerbates pressure overload-induced cardiac hypertrophy in aged hearts
|
Chang, W.-T.;Shih, J.-Y.;Lin, Y.-W.;Huang, T.-L.;Chen, Z.-C.;Chen, Chen C.-L.;Chu, J.-S.;Liu, P.Y. |
| 國立成功大學 |
2022 |
An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline
|
Chang, W.-T.;Liu, C.-F.;Feng, Y.-H.;Liao, C.-T.;Wang, J.-J.;Chen, Z.-C.;Lee, H.-C.;Shih, J.-Y. |
| 國立成功大學 |
2022 |
Comparison of Surgical or Medical Castration-Related Cardiotoxicity in Patients with Prostate Cancer
|
Kan, W.-C.;Hsieh, K.-L.;Chen, Y.-C.;Ho, C.H.;Hong, C.-S.;Chiang, Chiang C.-Y.;Wu, N.-C.;Chen, M.;Shih, J.-Y.;Chen, Z.-C.;Chang, W.-T. |
| 國立成功大學 |
2022 |
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities
|
Wu, N.-C.;Feng, Y.-H.;Kuo, Y.H.;Chen, W.-Y.;Wu, H.-C.;Huang, C.-T.;Wang, Wang W.-C.;Kang, N.-W.;Shih, J.-Y.;Chen, Z.-C.;Chang, W.-T. |
| 國立成功大學 |
2022 |
Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3
|
Chang, W.-T.;Shih, J.-Y.;Lin, Y.-W.;Chen, Z.-C.;Kan, W.-C.;Lin, T.-H.;Hong, C.-S. |
| 國立成功大學 |
2022 |
Regular use of aspirin is associated with a lower cardiovascular risk in prostate cancer patients receiving gonadotropin-releasing hormone therapy
|
Chang, W.-T.;Hong, C.-S.;Hsieh, K.-L.;Chen, Y.-C.;Ho, C.;Shih, J.-Y.;Kan, W.-C.;Chen, Z.-C.;Lin, Y.-C. |
| 國立成功大學 |
2022 |
Deletion of MicroRNA-21 Impairs Neovascularization Following Limb Ischemia: From Bedside to Bench
|
Chang, W.-T.;Lin, Y.-W.;Huang, P.-S.;Lin, Y.-C.;Tseng, S.-Y.;Chao, T.-H.;Chen, Z.-C.;Shih, J.-Y.;Hong, C.-S. |
| 國立成功大學 |
2022 |
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
|
Su, P.-L.;Chang, G.-C.;Hsiao, S.-H.;Hsia, T.-C.;Lin, M.-C.;Lin, M.-H.;Shih, J.-Y.;Yang, C.-T.;Yang, S.-H.;Chen, Y.-M. |
| 臺大學術典藏 |
2021-12-01T06:03:21Z |
Tracheal botryomycosis in a patient with tracheopathia osteochondroplastica
|
Shih J.-Y.; Hsueh P.-R.; Chang Y.-L.; Lee L.-N.; YEE-CHUN CHEN; Chen M.-F.; Luh K.-T. |
| 臺大學術典藏 |
2021-11-03T05:24:55Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
|
Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; CHONG-JEN YU; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-11-03T05:24:55Z |
Trait mindfulness and depressive symptoms in non-small cell lung cancer patients: the mediating roles of quality of life and meaning in life
|
Hsieh C.-C.; Ho C.-C.; Lin Z.-Z.; CHONG-JEN YU; Jow G.-M.; Huang F.-Y.; Shih J.-Y.; Hsiao F.-H. |
| 臺大學術典藏 |
2021-11-03T05:24:54Z |
Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan
|
Wu S.-G.; Liao W.-Y.; Su K.-Y.; Yu S.-L.; Huang Y.-L.; CHONG-JEN YU; Chih-Hsin Yang J.; Shih J.-Y. |
| 臺大學術典藏 |
2021-11-03T05:24:53Z |
Establishing aspergillus-specific igg cut-off level for chronic pulmonary aspergillosis diagnosis: Multicenter prospective cohort study
|
Lee M.-R.; Huang H.-L.; Keng L.-T.; Chang H.-L.; Sheu C.-C.; Fu P.-K.; Wang J.-Y.; Chong I.-W.; Shih J.-Y.; CHONG-JEN YU |
| 臺大學術典藏 |
2021-11-03T05:24:52Z |
Tyrosine kinase inhibitors improved survival of critically ill egfr-mutant lung cancer patients undergoing mechanical ventilation
|
Lee I.-H.; Yang C.-Y.; Shih J.-Y.; CHONG-JEN YU |
| 臺大學術典藏 |
2021-10-08T08:16:35Z |
The significance of visceral pleural surface invasion in 321 cases of non-small cell lung cancers with pleural retraction
|
Chang Y.-L.; MONG-WEI LIN; Shih J.-Y.; Wu C.-T.; Lee Y.-C. |
| 臺大學術典藏 |
2021-10-08T08:16:33Z |
Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ?2 cm in maximal dimension
|
MONG-WEI LIN; Wu C.-T.; Shih J.-Y.; Chang Y.-L.; Yang P.-C. |
| 臺大學術典藏 |
2021-10-08T08:16:13Z |
Multi-kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin-related protein 1
|
Chung K.-P.; Huang Y.-L.; Chen Y.-J.; Juan Y.-H.; Hsu C.-L.; Nakahira K.; Huang Y.-T.; MONG-WEI LIN; Wu S.-G.; Shih J.-Y.; Chang Y.-L.; Yu C.-J. |
| 臺大學術典藏 |
2021-10-04T07:15:44Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-10-04T07:15:41Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-10-04T07:15:39Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang S.-K.; JEN-CHANG KO; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-10-04T07:15:37Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-10-04T07:15:37Z |
Effect of β-Blocker in Treatment-Na?ve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs
|
Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Zhang J.-F.; Wang J.-Y.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-10-04T07:15:36Z |
Efficacy and safety of cone-beam computed tomography-derived augmented fluoroscopy combined with endobronchial ultrasound in peripheral pulmonary lesions
|
Yu K.-L.; Yang S.-M.; Ko H.-J.; Tsai H.-Y.; JEN-CHANG KO; Lin C.-K.; Ho C.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T05:56:07Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; LI-TA KENG; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T05:56:06Z |
Significant clinical factors associated with long-term mortality in critical cancer patients requiring prolonged mechanical ventilation
|
LI-TA KENG; Chung K.-P.; Lin S.-Y.; Liang S.-K.; Cheng J.-C.; Chen I.-C.; Chen Y.-F.; Chang H.-T.; Hsu C.-L.; Jerng J.-S.; Wang H.-C.; Kuo P.-H.; Wu H.-D.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T05:56:03Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; LI-TA KENG; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T05:56:02Z |
Establishing aspergillus-specific igg cut-off level for chronic pulmonary aspergillosis diagnosis: Multicenter prospective cohort study
|
Lee M.-R.; Huang H.-L.; LI-TA KENG; Chang H.-L.; Sheu C.-C.; Fu P.-K.; Wang J.-Y.; Chong I.-W.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T05:41:27Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Chen L.-Y.; Molina-Vila M.A.; Ruan S.-Y.; Su K.-Y.; Liao W.-Y.; KAI-LUN YU; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.H.; Rosell R.; Yang P.-C. |
| 臺大學術典藏 |
2021-09-17T05:41:26Z |
The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer
|
KAI-LUN YU; Tsai T.-H.; Ho C.-C.; Liao W.-Y.; Lin C.-K.; Hsu C.-L.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T05:41:23Z |
Efficacy and safety of cone-beam computed tomography-derived augmented fluoroscopy combined with endobronchial ultrasound in peripheral pulmonary lesions
|
KAI-LUN YU; Yang S.-M.; Ko H.-J.; Tsai H.-Y.; Ko J.-C.; Lin C.-K.; Ho C.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T03:21:19Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
SHENG-KAI LIANG; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T03:21:18Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
SHENG-KAI LIANG; Lee M.-R.; Liao W.-Y.; Ho C.-C.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T03:21:18Z |
Significant clinical factors associated with long-term mortality in critical cancer patients requiring prolonged mechanical ventilation
|
Keng L.-T.; Chung K.-P.; Lin S.-Y.; SHENG-KAI LIANG; Cheng J.-C.; Chen I.-C.; Chen Y.-F.; Chang H.-T.; Hsu C.-L.; Jerng J.-S.; Wang H.-C.; Kuo P.-H.; Wu H.-D.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T03:21:17Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
SHENG-KAI LIANG; Ko J.-C.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T03:21:16Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
SHENG-KAI LIANG; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T02:51:01Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; MENG-RUI LEE; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T02:50:57Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.; MENG-RUI LEE; Liao W.-Y.; Ho C.-C.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T02:50:52Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; MENG-RUI LEE; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T02:50:51Z |
Establishing aspergillus-specific igg cut-off level for chronic pulmonary aspergillosis diagnosis: Multicenter prospective cohort study
|
MENG-RUI LEE; Huang H.-L.; Keng L.-T.; Chang H.-L.; Sheu C.-C.; Fu P.-K.; Wang J.-Y.; Chong I.-W.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-15T01:20:52Z |
IGFBP7 Drives resistance to epidermal growth factor receptor tyrosine kinase inhibition in lung cancer
|
Wu S.-G.; Chang T.-H.; Tsai M.-F.; Liu Y.-N.; CHIA-LANG HSU; Chang Y.-L.; Yu C.-J.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-15T01:20:50Z |
MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process
|
Wang H.-Y.; Liu Y.-N.; Wu S.-G.; CHIA-LANG HSU; Chang T.-H.; Tsai M.-F.; Lin Y.-T.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-15T01:20:46Z |
Multi-kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin-related protein 1
|
Chung K.-P.; Huang Y.-L.; Chen Y.-J.; Juan Y.-H.; CHIA-LANG HSU; Nakahira K.; Huang Y.-T.; Lin M.-W.; Wu S.-G.; Shih J.-Y.; Chang Y.-L.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-09T05:25:29Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
ZONG-HAN YAO; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J. |
